February 18, 2021
Researchers at University of California San Diego School of Medicine identified new therapeutic targets for gastrointestinal stromal tumors (GISTs) that could lead to new treatment options for patients.
February 23, 2021
Scientists at University of California San Diego School of Medicine validated a more inclusive and comprehensive genetic tool, known as a polygenic hazard score (PHS), for predicting age of onset of aggressive prostate cancer.
April 26, 2021
A multi-institutional team of researchers, led by UC San Diego School of Medicine and Moores Cancer Center, has identified both the genetic abnormalities that drive pre-cancer cells into becoming an invasive type of head and neck cancer and patients who are least likely to respond to immunotherapy.
June 3, 2021
As the first designated medical center in San Diego certified to offer this type of immunotherapy, UC San Diego Health will begin treating patients this month.
October 13, 2021
UC San Diego researchers report that conducting genomic evaluations of advanced malignancies can be effective in guiding first-line-of-treatment, rather than waiting until standard-of-care therapies have failed.
March 21, 2022
UC San Diego Health is now administering Evusheld to eligible, immunocompromised patients to protect against the COVID-19 virus.
September 19, 2022
UC San Diego Health now offers a novel therapy option shown to extend the lifespan and improve quality of life for certain patients.
October 19, 2022
UC San Diego Health is now offering a new treatment for patients with low-grade upper tract urothelial cancer that could safely avoid removal of the entire kidney, which may prevent the need for dialysis or kidney transplant in the future.
November 10, 2022
An international symposium November 17-18, 2022 at UC San Diego will discuss current clinical trials using gene therapy, here and abroad.
April 25, 2023
New UC San Diego Health transperineal prostate biopsy procedure now offered in clinic setting.
